Market Overview

FDA Advisory Committee Votes to Recommend Isis' KYNAMRO

Share:
Related SNY
ENGAGE Randomized Clinical Trial Evaluating Cerdelgafor Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association
Sanofi Posts Higher Q4 Profit
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More (Seeking Alpha)

Genzyme,
a Sanofi company (NYSE: SNY), and Isis Pharmaceuticals
(NASDAQ: ISIS), announced today that the Endocrinologic and
Metabolic Drugs Advisory Committee of the U.S. Food and Drug
Administration (FDA) voted 9 to 6 that Genzyme had provided
sufficient efficacy and safety data to support the marketing of KYNAMRO™
(mipomersen sodium) for the treatment of patients with Homozygous
Familial Hypercholesterolemia (HoFH). Many people with HoFH have
aggressive cardiovascular disease beginning in childhood, and even with
today's therapies remain at significant risk of cardiovascular events.

"We are very encouraged by the support for KYNAMRO at today's Advisory
Committee meeting, which marks a significant and positive step in our

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global

 

Related Articles (ISIS + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→